KDR and cancer: In 2004, the first agent approved by the FDA was bevacizumab, a humanized form of anti-VEGF Ab, indicated in metastatic colon cancer [30], and 2 years later, ranibizumab, a recombinant antibody fragment from human, showed the effectiveness in intraocular for age-related macular degeneration treatment [31], Ziv-aflibercept (targets: VEGF-A, VEGF-B, and PlGF), ramucirumab (target: VEGFR-2), and multiple tyrosine kinase inhibitors are indicated in combination with other therapies for various cancers [32].